Koers Essex Bio-Technology Limited Deutsche Boerse AG
Aandelen
EB51
KYG312371035
Farmaceutische producten
Omzet 2022 | 1,32 mld. 169 mln. 157 mln. | Omzet 2023 | 1,71 mld. 218 mln. 203 mln. | Marktkapitalisatie | 1,41 mld. 181 mln. 168 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2022 | 225 mln. 28,8 mln. 26,78 mln. | Nettowinst (verlies) 2023 | 275 mln. 35,2 mln. 32,73 mln. | EV/omzet 2022 | 1,78 x |
Nettoliquiditeiten 2022 | 53,76 mln. 6,88 mln. 6,4 mln. | Nettoliquiditeiten 2023 | 221 mln. 28,29 mln. 26,3 mln. | EV/omzet 2023 | 0,7 x |
K/w-verhouding 2022 |
11
x | K/w-verhouding 2023 |
5,31
x | Werknemers | 1.481 |
Dividendrendement 2022 |
1,55% | Dividendrendement 2023 |
3,61% | Vrij verhandelbaar | 45,97% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Hai Zhou Fang
CEO | Chief Executive Officer | 58 | 31-07-00 |
Qi Xue
CTO | Chief Tech/Sci/R&D Officer | 63 | 09-04-18 |
Hian Leng Ngiam
BRD | Director/Board Member | 40 | 01-01-15 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Mia Je Ngiam
FOU | Founder | 70 | 01-02-99 |
Lai Man Yau
BRD | Director/Board Member | 60 | 01-01-01 |
Mee Mooi Yeow
BRD | Director/Board Member | 72 | 30-09-04 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+2,08% | 95,18 mld. | |
-4,34% | 37,55 mld. | |
+76,55% | 28,2 mld. | |
-14,61% | 15,63 mld. | |
-3,46% | 13,63 mld. | |
-12,31% | 11,5 mld. | |
+184,77% | 10,81 mld. | |
-54,13% | 9,23 mld. | |
+6,14% | 9,09 mld. |